Clinical trials: Psychologic Adaptation
Weight Gain
Comparison of Two Dose Adjustment Strategies of a Human Milk Protein Fortifier in Preterm Infants
The primary objective is to compare weight gain (g/day) of infants receiving new protein fortifier (PF) according to a blood urea nitrogen (BUN)-driven fortification regimen to weight gain (g/day) of infants receiving PF…
- Trial name
- NCT03604042
- Testing
- Protein fortifier
- Where
- France
- Volunteers
- 68 people
- Sponsor
- Société des Produits Nestlé (SPN)
Parenting Practices, Self Efficacy
Talk Parenting Education Program II
The goal of this clinical trial is to learn whether Talk Parenting, a voice-based program delivered through an Amazon Echo Dot (Alexa), can help parents and caregivers of children ages 3-5 years improve challenging bedtime and…
- Conditions
- Parenting Practices, Self Efficacy, Stress, Child Behavior
- Trial name
- TP2 (NCT07462052)
- Testing
- The Talk Parenting Program
- Where
- United States
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Oregon Research Behavioral Intervention Strategies, Inc.
Secondary Hyperparathyroidism
Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia
The purpose of this study is to evaluate the efficacy and the safety of KHK7580 orally administered once daily for 52 weeks compared to cinacalcet hydrochloride as an active control in subjects with secondary hyperparathyroidism…
- Trial name
- NCT03822507
- Testing
- KHK7580, Cinacalcet Hydrochloride
- Where
- 34 sites in China, Hong Kong and 2 more
- Volunteers
- 404 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Hypothyroidism
Study of Dose Adjustment From Levothyroxine to a New Levothyroxine Sodium Test Formulation
The purpose of this study is to investigate the effect of switching participants taking levothyroxine to a new sodium formulation.
- Trial name
- NCT01916304
- Testing
- Levothyroxine sodium new formulation
- Where
- Belgium
- Volunteers
- 101 people
- Sponsor
- Takeda
Coronary Artery Disease, Cardiovascular Diseases
Clinical Study for the Investigation and Validation of a Therapy Procedure for the Adjustment of Risk Factors in Patients With Coronary Heart Disease by Means of Digital Therapy Control
This study will test a controlled investigation of the efficacy and effectiveness of iATROS digital therapy management for risk factor adjustment in patients with coronary heart disease (CHD).
- Conditions
- Coronary Artery Disease, Cardiovascular Diseases, Coronary Heart Disease, Ischemic Heart Disease
- Trial name
- ERKHA (NCT06091774)
- Testing
- CHD therapy through iATROS medical device
- Where
- Germany
- Volunteers
- 1,000 people
- Sponsor
- iATROS GmbH
Hyperthyroidism, Graves Disease
AI-Based Wearable Monitoring (Glandy HYPER) for Antithyroid Drug Dose Adjustment in Graves' Disease
Graves' disease is the most common cause of hyperthyroidism and is usually treated with antithyroid drugs such as methimazole (MMI).
- Conditions
- Hyperthyroidism, Graves Disease, Thyrotoxicosis
- Trial name
- NCT07857421
- Testing
- Glandy HYPER (AI-based monitoring software), Methimazole
- Where
- 2 sites in Germany
- Volunteers
- 30 people
- Sponsor
- THYROSCOPE INC.
Type 2 Diabetes Mellitus
Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)
Primary Objective: To demonstrate that the simple daily titration algorithm is non-inferior to the weekly titration algorithm according to Canadian labeling.
- Trial name
- LixilanOne CAN (NCT03767543)
- Testing
- INSULIN GLARGINE/LIXISENATIDE HOE901/AVE0010
- Where
- 32 sites in Canada
- Volunteers
- 265 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine
This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim of the trial is to compare the efficacy and safety of two different titration algorithms for insulin degludec/insulin aspart…
- Trial name
- BOOST® (NCT01680341)
- Testing
- insulin degludec/insulin aspart
- Where
- 45 sites in United States, Algeria and 3 more
- Volunteers
- 272 people
- Sponsor
- Novo Nordisk A/S
Adjustment Disorder
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to…
- Trial name
- NCT07002034
- Testing
- RE104 for Injection
- Where
- 32 sites in United States
- Volunteers
- 100 people
- Sponsor
- Reunion Neuroscience Inc
Cataract
Check of Optical Features and Accuracy of the Zeiss ZO Lens After Selection and Calculation With OKULIX
It is planned to implant the intraocular lenses XL Stabi ZO and Invent ZO into the eyes of patients for whom a cataract operation is medically indicated. The lenses are marketed and CE certified.
- Trial name
- ZO Okulix (NCT00842959)
- Testing
- Invent ZO, XL Stabi ZO
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- Carl Zeiss Meditec AG
Overactive Bladder, Urinary Urge Incontinence
A Sham-Controlled Study to Evaluate the Safety and Efficacy of a Smart, Self-Adjusting, Surgery-Free, Wearable Bladder Neuromodulation System for Overactive Bladder
This is a prospective, multi-center, sham-controlled study comparing the safety and effectiveness of the self-adjusting, surgery-free, wearable Active System to a Sham System on adult Subjects diagnosed with OAB.
- Conditions
- Overactive Bladder, Urinary Urge Incontinence, Urge Incontinence
- Trial name
- REDUCEOAB (NCT05381116)
- Testing
- Avation System
- Where
- 6 sites in United States
- Volunteers
- 125 people
- Sponsor
- Avation Medical, Inc.
Adjustment Disorder, Adjustment Disorder With Anxious Mood
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
This study is assessing the efficacy and safety of NPX-5 in psilocybin-assisted psychotherapy for the treatment of adjustment disorder due to cancer diagnosis.
- Conditions
- Adjustment Disorder, Adjustment Disorder With Anxious Mood, Cancer, Cancer Cachexia
- Trial name
- NCT07072728
- Testing
- Psilocybin therapy
- Where
- 3 sites in Australia
- Volunteers
- 87 people
- Sponsor
- Psyence Australia Pty Ltd
Carcinoma, Non-Small-Cell Lung
Real World Data on Gi(l)Otrif® Dose Adjustment
This is a non-interventional, multi-country, multi-site study based on existing data from medical records of patients treated with Gi(l)otrif® as part of the routine treatment according to the approved label.
- Trial name
- NCT02751879
- Where
- 29 sites in United States, Austria and 11 more
- Volunteers
- 228 people
- Sponsor
- Boehringer Ingelheim
ER+ Breast Cancer
Tamoxifen Dose Adjustment on Indonesian Female ER+ Breast Cancer Patients Based on CYP2D6 Genotype and Endoxifen Levels
The objectives of this study is to perform CYP2D6 genotyping and metabolite concentrations analysis on ER+ breast cancer patients who are taking tamoxifen and give dose recommendations based on the CYP2D6 genotypes and endoxifen…
- Trial name
- NCT04312347
- Testing
- Tamoxifen dose adjustment
- Where
- Indonesia
- Volunteers
- 151 people
- Sponsor
- Nalagenetics Pte Ltd
Bipolar Disorder
Subjective Well Being of Patients Receiving Atypical Antipsychotics as Monotherapy or Cotherapy With Mood Stabilizers
Cross - Sectional study requiring one visit at the investigators office for the data collection. Target Group: Patients that suffer from Bipolar Disorder Type 1.
- Trial name
- DIDAXI (NCT00691353)
- Where
- 20 sites in Greece
- Volunteers
- 540 people
- Sponsor
- AstraZeneca
Chronic Motor or Vocal Tic Disorder, Tourette's Disorder
Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder
The purpose of this trial is to demonstrate the efficacy and safety of aripiprazole in children and adolescents aged 6~18 years with chronic tic disorders or Tourette's disorder
- Trial name
- NCT00706589
- Testing
- aripiprazole
- Where
- 6 sites in South Korea
- Volunteers
- 61 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Work Related Stress, Psychologic Adaptation
CO-ADAPT: Adaptive Environments and Conversational Agent Based Approaches for Healthy Ageing and Work Ability
The purpose of this study is to identify effective methodologies to help people improve their ability to adapt to psychological stress.
- Trial name
- NCT04809090
- Testing
- SMT, App CA
- Where
- Italy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Tommaso Ciulli
Diabetes, Diabetes Mellitus, Type 2
Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes
This trial is conducted in the United States of America (USA). This trial aims for a comparison of the safety and efficacy in subjects with type 2 diabetes using either self titration or physician guided titration according to…
- Trial name
- PREDICTIVE™ (NCT00264901)
- Testing
- insulin detemir
- Where
- United States
- Volunteers
- 5,652 people
- Sponsor
- Novo Nordisk A/S
Cerebral Atherosclerosis
Clinical Trial of Efficacy and Safety of Divaza for Adjustment of Oxidative Disorders in Patients With Cerebral Atherosclerosis
The purpose of this study is to obtain additional data on efficacy and safety of Divaza for adjustment of oxidative disorders in patients with cerebral atherosclerosis.
- Trial name
- NCT03485495
- Testing
- Divaza
- Where
- 10 sites in Russia
- Volunteers
- 124 people
- Sponsor
- Materia Medica Holding
Cardiovascular Disease
Evaluation of a New Thermostable Formulation of FLOLAN in Japanese Subjects
This study is a Phase IV, open-label, single-arm study to assess the safety and the necessity of dose adjustment after switching to FLOLAN injection prepared with the reformulated diluent in Japanese patients with PAH who are…
- Trial name
- NCT02705807
- Testing
- FLOLAN injection with currently marketed diluent, FLOLAN injection with reformulated diluent
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline